EyePoint Pharmaceuticals, Inc. (EYPT) News
EyePoint Pharmaceuticals, Inc. (EYPT)
Today's Latest Price: $0.53 USD
Updated Dec 2 6:55pm
Add EYPT to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
Filter EYPT News Items
EYPT News Results
| Event/Time | Symbol | Company | News Detail | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest EYPT News From Around the Web
Below are the latest news stories about EyePoint Pharmaceuticals Inc that investors may wish to consider to help them evaluate EYPT as an investment opportunity.
The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis StudyScaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3) Akouos Inc (NASDAQ: AKUS ) FibroGen Inc (NASDAQ: FGEN )(reacted to an adverse clinical readout for a rival drug to treat chronic kidney disease related anemia) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) Sutro Biopharma Inc (NASDAQ: STRO ) ( reacted to announcement concerning presentation of positive data for ovarian cancer drug) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 3) Akebia Therapeutics Inc (NASDAQ: AKBA ) (announced negative safety results for a late-stage study of drug to treat chronic kidney disease-induced anemia) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Genfit SA (NASDA... |
The Daily Biotech Pulse: Sanofi, GSK Begin Phase 1/2 Coronavirus Vaccine Study, Fulgent Strikes COVID-19 Testing Deal, New Data From NovavaxScaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Acutus Medical Inc (NASDAQ: AFIB ) Akouos Inc (NASDAQ: AKUS ) Avid Bioservices Inc (NASDAQ: CDMO ) ( reacted to strong quarterly results) BioLife Solutions Inc (NASDAQ: BLFS ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Edwards Lifesciences Corp (NYSE: EW ) Evogene Ltd (NASDAQ: EVGN ) Fortress Biotech (NASDAQ: FBIO ) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) (priced its 5.27-million-share common stock offering at $33 per share) Inspire Medical Systems Inc (NYSE: INSP ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Silk Road Medical Inc (NASDAQ: SILK ) Shockwave Medical Inc (NASDAQ: SWAV ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Twist Bioscience Corp ... |
EyePoint Pharma slips 7% on Dexcyu dealEyePoint Pharmaceuticals (EYPT) has entered into a purchase and marketing agreement for Dexcyu (dexamethasone intraocular suspension) 9% with Vantage Outsourcing, a cataract surgical service provider to a variety of hospitals, ambulatory surgery centers and physicians.The agreement will enable customers in the Vantage Outsourcing network, which spans over a 25+ state service... |
EyePoint Pharmaceuticals News: Why EYPT Stock Is Soaring 21% TodayEyePoint Pharmaceuticals (EYPT) news from yesterday concerning a massive deal has EYPT stock continuing to climb higher on Friday. |
34 Stocks Moving in Friday's Pre-Market SessionGainers EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) shares rose 94.8% to $1.12 in pre-market trading. Eyepoint Pharmaceuticals shares gained around 11% on … |
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOsScaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) Avenue Therapeutics Inc (NASDAQ: ATXI ) Checkmate Pharmaceuticals Inc (NASDAQ: CMPI ) DarioHealth Corp (NASDAQ: DRIO ) iTeos Therapeutics Inc (NASDAQ: ITOS ) Merit Medical Systems, Inc. (NASDAQ: MMSI ) Natera Inc (NASDAQ: NTRA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Otonomy Inc (NASDAQ: OTIC ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Pacira Biosciences Inc (NASDAQ: PCRX ) PDL BioPharma Inc (NASDAQ: PDLI ) Principia Biopharma Inc (NASDAQ: PRNB ) Qiagen NV (NYSE: QGEN ) Shockwave Medical Inc (NASDAQ: SWAV ) Silk Road Medical Inc (NASDAQ: SILK ) Syros Pharmaceuticals Inc (NASDAQ: SYRS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 18) Acorda Therapeutics Inc (NASDAQ: ACOR ) Alector Inc (NASDAQ: AL... |
EyePoint Pharmaceuticals EPS beats by $0.01, beats on revenueEyePoint Pharmaceuticals (EYPT): Q2 GAAP EPS of -$0.10 beats by $0.01.Revenue of $4.12M (-42.9% Y/Y) beats by $0.33M.Net product revenue declined 44.8% Y/Y to $3.7M with $2.9M for YUTIQ and $0.8M for DEXYCU.Shares +3.44% PM.Press Release... |
EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce U.S. Commercial Alliance for DEXYCU®\- Collaboration to bring DEXYCU to ImprimisRx’s established customer base of ophthalmologists, hospitals, and ambulatory surgical centers -WATERTOWN, Mass. and NASHVILLE, Tenn., Aug. 04, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to |
EyePoint Pharmaceuticals Announces Second Quarter 2020 Financial Results Release Date and Conference Call InformationWATERTOWN, Mass., July 29, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its second quarter 2020 on Wednesday, August 5, 2020. Management will host a conference call to review the results at 8:30 AM ET on the same day. The conference call may be accessed by dialing (877) 312-7507 from the U.S. and Canada or (631) 813-4828 from international locations. The conference ID is 5816799. A live webcast will be available on the Investor Relations section of the corporate website at http://www.eyepointpharma.com. A webcast replay will also be available on the corporate website at the conclusion of the call.About EyePoint PharmaceuticalsEyePoint P... |
EyePoint Pharmaceuticals Expands Executive Leadership Team with the Appointment of Jay S. Duker, M.D., as Chief Strategic Scientific Officer- World-renowned retina specialist to lead EYP-1901 development efforts and support expansion of EyePoint’s ocular disease pipeline - WATERTOWN, Mass.,… |
